Insulet Corp. (PODD) recently announced that its Omnipod 5 Automated Insulin Delivery ("AID") system is now available in France with Dexcom's (DXCM) G6 sensor integration. Additionally, the company made the full commercial launch of the system with G7 compatibility in the United States and rolled out the Omnipod 5 App through a limited market release for iPhone. More on the Latest Achievements Additionally, Insulet began the highly anticipated limited market release of the Omnipod 5 App for iPhone users in ...

Insulet Corporation (PODD) is primed for growth in the coming quarters as its revolutionary Omnipod 5 offering continues to successfully drive market growth. The company is making remarkable progress in terms of its key strategic imperatives to help patients in their diabetes management. Sound financial stability further instills optimism. The developer, manufacturer and distributor of insulin delivery systems has a market capitalization of $13.46 billion. Insulet projects a long-term estimated earnings gro ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style ...

Insulet Corporation (PODD) reported GAAP earnings per share (EPS) of 73 cents for first-quarter 2024, which significantly improved from the year-ago period's EPS of 34 cents. The figure also exceeded the Zacks Consensus Estimate by 87.2%. First-quarter 2023 adjusted earnings per share were 23 cents. Revenues Revenues in the first quarter totaled $441.7 million, beating the Zacks Consensus Estimate by 4.3%. The top line jumped 23.3% year over year (up 22.8% at the constant exchange rate or CER). CER growth e ...

Forward Looking Statement Risks and uncertainties include, but are not limited to our dependence on a principal product platform; the impact of competitive products, technological change and product innovation; our ability to maintain an effective sales force and expand our distribution network; our ability to maintain and grow our customer base; our ability to scale the business to support revenue growth; our ability to secure and retain adequate coverage or reimbursement from third-party payors; the impac ...

France launch. Ana Maria Chadwick The France launch. Unidentified Analyst The timing of France. Yeah. Ana Maria Chadwick So, yeah -- I'll start. I mean, as we've said, the timing of the France launch will be here over the summer, and the teams are ready. They worked out all the pricing, and they're working all the salesforce and everything. So, we expect -- as we mentioned, that every country is slightly different. In France, there tends to be more of this fouryear cycle of contract renewals, as people migh ...

Insulet (PODD) reported $441.7 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 23.4%. EPS of $0.73 for the same period compares to $0.23 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $423.52 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +87.18%, with the consensus EPS estimate being $0.39.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ho ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended March 31, 2024 OR Washington, D.C. 20549 _____________________________________________________ Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 ___________________________________________________________ INSULET CORPORATION (Exact name of ...

Exhibit 99.1 Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue and Operating Margin Guidance ACTON, Mass. - May 9, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2024. First Quarter Financial Highlights: • First quarter 2024 revenue of $441.7 million, up 23.3%, or 22.8% in const ...

Analysts on Wall Street project that Insulet (PODD) will announce quarterly earnings of $0.39 per share in its forthcoming report, representing an increase of 69.6% year over year. Revenues are projected to reach $423.52 million, increasing 18.3% from the same quarter last year.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this perio ...